Multiple Sclerosis Drugs - Lebanon

Lebanon

Highlights

The Multiple Sclerosis Drugs market in Lebanon is expected to witness a significant increase in revenue, reaching US$5.05m in 2024.
Furthermore, it is projected to display a steady annual growth rate (CAGR 2024-2029) of -0.11%, leading to a market volume of US$5.02m by 2029.
When compared globally, United States is predicted to generate the highest revenue, amounting to US$11.77bn in 2024.
Lebanon's market for Multiple Sclerosis Drugs is witnessing a surge in demand due to an increasing prevalence of the disease in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Multiple Sclerosis Drugs market in Lebanon has seen significant growth in recent years.

Customer preferences: Lebanon has a high prevalence of Multiple Sclerosis (MS) compared to other countries in the Middle East. MS is a chronic and debilitating disease of the central nervous system that affects young adults. Patients suffering from MS require long-term treatment, which has led to a high demand for MS drugs in the country.

Trends in the market: The MS drugs market in Lebanon has seen significant growth due to the increasing prevalence of MS in the country. The market is dominated by a few multinational pharmaceutical companies that offer a range of drugs for the treatment of MS. However, the market is also witnessing the entry of new players who are offering biosimilar drugs at a lower cost. This is expected to increase competition in the market and lead to a reduction in drug prices.

Local special circumstances: Lebanon is facing an economic crisis, which has led to a shortage of foreign currency. This has impacted the availability of MS drugs in the country, as pharmaceutical companies are struggling to import drugs due to a lack of foreign currency. This has resulted in a shortage of drugs and an increase in drug prices, making it difficult for patients to access treatment.

Underlying macroeconomic factors: The economic crisis in Lebanon has had a significant impact on the healthcare sector. The shortage of foreign currency has led to a shortage of drugs, medical supplies, and equipment. This has made it difficult for patients to access healthcare services, including MS drugs. The political instability in the country has also contributed to the economic crisis, making it difficult for the government to provide adequate funding for the healthcare sector. In conclusion, the MS drugs market in Lebanon has seen significant growth due to the increasing prevalence of MS in the country. However, the economic crisis and shortage of foreign currency have impacted the availability of drugs, making it difficult for patients to access treatment. The entry of new players offering biosimilar drugs is expected to increase competition in the market and lead to a reduction in drug prices.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.